Activist Investor 13D, 13G Filings


This page shows a list of all the recent 13D/G filings made by Sofinnova Venture Partners IX, L.P.. Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

DateForm Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2018‑10‑10 SC 13D ETTX / Entasis Therapeutics Holdings Inc. 1,180,178 9.0
2018‑06‑08 SC 13D ITRM / Iterum Therapeutics plc 1,726,514 12.4
2018‑05‑24 SC 13D/A LIFE / aTyr Pharma, Inc. 1,867,173 1,694,528 -9.25 5.7 -31.33
2018‑02‑14 SC 13G/A BOLD / Audentes Therapeutics, Inc. 1,380,303 1,380,303 0.00 4.6 -30.30
2017‑09‑27 SC 13D/A MRUS / Merus N.V. 1,401,403 1,750,099 24.88 9.0 -1.10
2017‑02‑03 SC 13G/A CHMA / Chiasma, Inc. 1,215,656 1,767,102 45.36 7.2 41.18
2016‑10‑27 SC 13D/A ASND / Ascendis Pharma AS 1,703,199 2,238,264 31.42 7.1 4.41
2016‑07‑27 SC 13G BOLD / Audentes Therapeutics, Inc. 1,380,303 6.6
2016‑05‑27 SC 13D MRUS / Merus N.V. 1,401,403 9.1
2016‑03‑16 SC 13D/A EDGE / Edge Therapeutics, Inc. 2,311,368 2,852,711 23.42 9.9 22.22
2016‑02‑11 SC 13G CHMA / Chiasma, Inc. 1,215,656 5.1
2015‑10‑14 SC 13D EDGE / Edge Therapeutics, Inc. 2,311,368 8.1
2015‑09‑09 SC 13D/A ASND / Ascendis Pharma AS 1,703,199 6.8
2015‑05‑15 SC 13D LIFE / aTyr Pharma, Inc. 1,867,173 8.3